Cochrane Evidence Synthesis and Methods ►

Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To compare the blood pressure effects of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists with the blood pressure effects of glucagon-like peptide-1 (GLP-1) receptor agonists.

This is a protocol.

Published:

16 April 2025

Authors:

Grenet G, Gougeon A, Salzwedel DM, Jauca CD, Wright JM

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Grenet G, Gougeon A, Salzwedel DM, Jauca CD, Wright JM. Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists (Protocol). Cochrane Database of Systematic Reviews 2025, Issue 4. Art. No.: CD016144. DOI: 10.1002/14651858.CD016144.